It enters the pores of open voltage-gated potassium channels, where it slows potassium efflux. The resulting reduction in outward potassium movement prolongs the action potential rather than simply initiating a new signal. This open-state dependence helps explain why the compound is useful for examining how potassium channels shape neuronal electrical activity.
Prolonged action potentials can enhance neurotransmitter release from neurons. Thus, blocking potassium channels links membrane-level ion movement to synaptic communication: slower potassium efflux extends the electrical event, and the extended event can increase transmitter output. This relationship makes the compound useful when investigators want to connect ion-channel behavior with synaptic transmission.
Because the same increase in neuronal excitability that may improve electrical signaling can become excessive. The overview identifies seizures and other adverse effects as risks when potassium-channel inhibition is too great. This creates a clinically important balance: sufficient channel blockade may support conduction, whereas excessive blockade can disturb normal neuronal activity.
Multiple sclerosis can impair saltatory conduction when myelin is disrupted. Under those conditions, prolonging action potentials through potassium-channel blockade may help electrical signals move through neurons with impaired conduction. Fampridine therefore targets a conduction problem rather than the underlying demyelination itself, and its intended clinical benefit is improved walking ability in some people with multiple sclerosis.
They use the compound as a pharmacological probe of voltage-gated potassium-channel function, neuronal excitability, and synaptic transmission. Observing how channel blockade changes action-potential duration or neurotransmitter release helps relate potassium efflux to neuronal signaling. Its value is therefore experimental as well as therapeutic, allowing channel mechanisms to be studied in relevant neural systems.
Fampridine, the medical form associated with this mechanism, is used to improve walking ability in some people with multiple sclerosis. The rationale follows from demyelination-related disruption of saltatory conduction: prolonging neuronal action potentials can enhance signaling in affected pathways. The expected outcome is functional improvement in walking, not a universal benefit for every person with the disease.